[Sex hormone dependency in diffuse carcinoma of the stomach and results of chemo-endocrine therapy].
Based on experimental study that the growth of diffuse carcinoma of the stomach depended on sex hormone, chemo-endocrine therapy using an anti-estrogen after gastrectomy for female patients are carrying out in National Cancer Center Hospital since 1980. The results are as follows. The cumulative 3 year survival rate in 21 patients with chemo-endocrine therapy (TAM+) revealed significant higher (45.8%) than those (7.4%) in 23 patients with chemotherapy alone (TAM-). The results of TAM(+) in curatively resected cases (8 cases) were both 100% of 2 and 3 year survival rate with 2 recurrent cases. In TAM(-) 10 cases, 2 and 3 year survival rate showed 56.0% and 20.0% respectively (P less than 0.01). This study suggests that the chemo-endocrine therapy may be a new adjuvant therapy in female patients with diffuse carcinoma of the stomach.